Shaanxi Micot Pharmaceutical Technology

2335 · HKEX

Public Market Listing

2335HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Shaanxi Micot Pharmaceutical Technology are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
CaSR; OGPPeptide
Chronic Kidney Disease
Secondary Hyperparathyroidism

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
November 2026 (1)
MT1013Phase 3Secondary Hyperparathyroidism, Chronic Kidney Disease
Est. primary completion 2026-11-26 · NCT07122401 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1$0$5.5M—$6.9Mreport ↗

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0$15M—$22Mreport ↗

In the 2024 fiscal year, the company reported revenue of $0M (prior year $0M), with no operating revenue generated. R&D spend was $14.89M, up 21.0% YoY from $12.31M. Cash and equivalents were not disclosed, and net income/loss was not disclosed; the quarterly net burn was $21.85M.

The company filed a Hong Kong IPO prospectus in late September 2025, with CCB International and China Merchants Securities International as joint sponsors. Its lead candidate MT1013, a dual-target receptor agonist for secondary hyperparathyroidism, completed a Phase II trial and entered Phase III. Other key pipeline assets include XTL6001, a triple-target agonist in Phase I for weight management, and MT1002 and MT200605, both of which have completed Phase I and are advancing to Phase II studies.

View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-FY$0$12M—$28Mreport ↗